Table 1
Age (years) | 28.9 ± 4.8 |
Gender | Â |
Male (M) | 6 |
Female (F) | 9 |
Body Surface Area (m2) | 1.56 ± 0.1 |
Deferoxamine dose (mg/kg) | 38 ± 10.2 |
| Â | 5.3 days/week |
CMR measures: | Â |
Myocardial T2* (ms) [>20] | 5.7 ± 1.0 |
Liver T2* (ms) [>19] | 3.7 ± 2.9 |
LV end diastolic volume index (mL/m2) [M:45–152, F:54–121] | 87.1 ± 31.6 |
LV end systolic volume index (mL/m2) [M:13–34, F:6–35] | 44.4 ± 24.9 |
LV ejection fraction (%) [M > 59%; F > 63%] | 51.2 ± 10.9 |
Blood measures: | Â |
Transfusional red blood cell input (mL/kg/year) | 155.1 ± 40.9 |
Mean year hemoglobin (g/dL) | 11.0 ± 1.2 |
Hepatitis C positive | Â |
Yes | 14 |
No | 1 |
Biochemistry | Â |
Serum ferritin (μg/L) [M: 5–104, F: 4–254 ] | 2057 ± 7.6 |
Alanine aminotransferase (IU/L) [5-35] | 53.4 ± 34.8 |
BNP (pmol/L) [<100] | 26.0 (9.8–758) |
Serum creatinine (mg/dL) [0.6–1.2] | 0.68 ± 0.19 |